Early identification of sepsis

被引：35

作者：

Gonsalves M.D. ^{[1
]}

Sakr Y. ^{[1
]}

机构：

[1] Department of Anesthesiology and Intensive Care, Friedrich Schiller University Hospital, Jena 07743

来源：

Current Infectious Disease Reports | 2010年 / 12卷 / 5期

关键词：

Biomarkers; Cytokines; Early diagnosis; Hybridization; Microarrays; Multiplex; Polymerase chain reaction; Procalcitonin; Sepsis;

D O I：

10.1007/s11908-010-0122-3

中图分类号：

学科分类号：

摘要：

Early diagnosis is crucial to reduce morbidity and mortality from sepsis. Clinical suspicion is the first step to diagnosis, and necessitates meticulous history taking and complete clinical examination. Special attention should be paid to identifying foci of infection. Biomarkers of host response-including acute phase proteins, procalcitonin, and various cytokines-may be useful in the diagnosis and management of patients with sepsis. Rapid and reliable detection of pathogens and their antibiotic susceptibility patterns is also of utmost importance. Many new techniques have been developed to shorten the time required for pathogen detection, including nucleic acid-based technologies (eg, polymerase chain reaction, microarrays, and hybridization). The detection of pathogen-related antigens is another approach that is useful in the diagnosis of fungal infections, targeting fungal cell wall components such as galactomannan and (1→3)-β-D-glucan. © 2010 Springer Science+Business Media, LLC.

引用

页码：329 / 335

页数：6

共 52 条

[1]

Martin G.S., Mannino D.M., Eaton S., Et al., The epidemiology of sepsis in the United States from 1979 through 2000, N Engl J Med, 348, pp. 1546-1554, (2003)

[2]

Vincent J.L., Rello J., Marshall J., Et al., International study of the prevalence and outcomes of infection in intensive care units, JAMA, 302, pp. 2323-2329, (2009)

[3]

Dellinger R.P., Carlet J.M., Masur H., Et al., Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock, Crit Care Med, 32, pp. 858-873, (2004)

[4]

Hyatt J.M., McKinnon P.S., Zimmer G.S., Et al., The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents, Clin Pharmacokinet, 28, pp. 143-160, (1995)

[5]

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, Crit Care Med, 20, pp. 864-874, (1992)

[6]

Levy M.M., Fink M.P., Marshall J.C., Et al., 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference, Crit Care Med, 31, pp. 1250-1256, (2003)

[7]

Calandra T., Cohen J., The international sepsis forum consensus conference on definitions of infection in the intensive care unit, Crit Care Med, 33, pp. 1538-1548, (2005)

[8]

Sakr Y., Reinhart K., Biomarkers of host response

[9]

Diagnostic purposes, Sepsis Handbook, pp. 94-103, (2008)

[10]

Bouadma L., Luyt C.E., Tubach F., Et al., Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial, Lancet, 375, pp. 463-474, (2010)

← 1 2 3 4 5 6 →